

Eduardo Magalhães Rego

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7931489/publications.pdf>

Version: 2024-02-01

264
papers

6,109
citations

117453

34
h-index

98622

67
g-index

274
all docs

274
docs citations

274
times ranked

7790
citing authors

#	ARTICLE	IF	CITATIONS
1	Acute Promyelocytic Leukemia. , 2015, , 51-54.		448
2	Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood, 2019, 133, 1630-1643.	0.6	393
3	Dyskeratosis Congenita and Cancer in Mice Deficient in Ribosomal RNA Modification. Science, 2003, 299, 259-262.	6.0	387
4	Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiency. Nature, 2008, 456, 971-975.	13.7	385
5	Impaired Control of IRES-Mediated Translation in X-Linked Dyskeratosis Congenita. Science, 2006, 312, 902-906.	6.0	363
6	Active Pin1 is a key target of all-trans retinoic acid in acute promyelocytic leukemia and breast cancer. Nature Medicine, 2015, 21, 457-466.	15.2	220
7	Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 10173-10178.	3.3	193
8	Two Critical Hits for Promyelocytic Leukemia. Molecular Cell, 2000, 6, 1131-1141.	4.5	146
9	Role of Promyelocytic Leukemia (Pml) Protein in Tumor Suppression. Journal of Experimental Medicine, 2001, 193, 521-530.	4.2	145
10	Clinical features and outcomes of 134 Brazilians with acute promyelocytic leukemia who received ATRA and anthracyclines. Haematologica, 2007, 92, 1431-1432.	1.7	131
11	Identification of a myeloid committed progenitor as the cancer-initiating cell in acute promyelocytic leukemia. Blood, 2009, 114, 5415-5425.	0.6	126
12	Maturing Mycobacterium smegmatis peptidoglycan requires non-canonical crosslinks to maintain shape. ELife, 2018, 7, .	2.8	108
13	Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL. Blood, 2013, 121, 1935-1943.	0.6	96
14	Leukemia with distinct phenotypes in transgenic mice expressing PML/RAR $\hat{\pm}$, PLZF/RAR $\hat{\pm}$ or NPM/RAR $\hat{\pm}$. Oncogene, 2006, 25, 1974-1979.	2.6	78
15	Management of APL in Developing Countries: Epidemiology, Challenges and Opportunities for International Collaboration. Hematology American Society of Hematology Education Program, 2006, 2006, 162-168.	0.9	75
16	Anti-inflammatory effects of atorvastatin: Modulation by the T-786C polymorphism in the endothelial nitric oxide synthase gene. Atherosclerosis, 2007, 193, 438-444.	0.4	71
17	Determination of P-glycoprotein, MDR-related protein 1, breast cancer resistance protein, and lung-resistance protein expression in leukemic stem cells of acute myeloid leukemia. Cytometry Part B - Clinical Cytometry, 2008, 74B, 163-168.	0.7	67
18	Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma. American Journal of Hematology, 2012, 87, 948-952.	2.0	63

#	ARTICLE	IF	CITATIONS
19	FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. <i>Annals of Oncology</i> , 2015, 26, 2155-2161.	0.6	63
20	(+)Î±-Tocopheryl succinate inhibits the mitochondrial respiratory chain complex I and is as effective as arsenic trioxide or ATRA against acute promyelocytic leukemia in vivo. <i>Leukemia</i> , 2012, 26, 451-460.	3.3	60
21	High expression of AURKA and AURKB is associated with unfavorable cytogenetic abnormalities and high white blood cell count in patients with acute myeloid leukemia. <i>Leukemia Research</i> , 2011, 35, 260-264.	0.4	58
22	Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study. <i>Annals of Hematology</i> , 2014, 93, 2001-2010.	0.8	58
23	Decolouration of Orange II solutions by TiO ₂ and ZnO active layers screen-printed on ceramic tiles under sunlight irradiation. <i>Applied Catalysis A: General</i> , 2009, 355, 109-114.	2.2	57
24	Reciprocal products of chromosomal translocations in human cancer pathogenesis: key players or innocent bystanders?. <i>Trends in Molecular Medicine</i> , 2002, 8, 396-405.	3.5	51
25	Role of Microparticles in the Hemostatic Dysfunction in Acute Promyelocytic Leukemia. <i>Seminars in Thrombosis and Hemostasis</i> , 2010, 36, 917-924.	1.5	49
26	Increased expression of miR-221 is associated with shorter overall survival in T-cell acute lymphoid leukemia. <i>Experimental Hematology and Oncology</i> , 2013, 2, 10.	2.0	49
27	Co-occurrence of DNMT3A, NPM1, FLT3 mutations identifies a subset of acute myeloid leukemia with adverse prognosis. <i>Blood</i> , 2020, 135, 870-875.	0.6	48
28	Age-related changes of lymphocyte subsets in normal bone marrow biopsies. , 1998, 34, 22-29.		46
29	Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials. <i>BMC Infectious Diseases</i> , 2021, 21, 1170.	1.3	46
30	Post-Sepsis State Induces Tumor-Associated Macrophage Accumulation through CXCR4/CXCL12 and Favors Tumor Progression in Mice. <i>Cancer Immunology Research</i> , 2016, 4, 312-322.	1.6	45
31	In vivo analysis of the role of aberrant histone deacetylase recruitment and RARÎ± blockade in the pathogenesis of acute promyelocytic leukemia. <i>Journal of Experimental Medicine</i> , 2006, 203, 821-828.	4.2	42
32	Therapeutic leukapheresis in patients with leukostasis secondary to acute myelogenous leukemia. <i>Journal of Clinical Apheresis</i> , 2011, 26, 181-185.	0.7	42
33	Characterization of Conserved and Novel Septal Factors in <i>Mycobacterium smegmatis</i> . <i>Journal of Bacteriology</i> , 2018, 200, .	1.0	42
34	Potential roles of microRNA-29a in the molecular pathophysiology of T-cell acute lymphoblastic leukemia. <i>Cancer Science</i> , 2015, 106, 1264-1277.	1.7	41
35	Profiling Three-Dimensional Nuclear Telomeric Architecture of Myelodysplastic Syndromes and Acute Myeloid Leukemia Defines Patient Subgroups. <i>Clinical Cancer Research</i> , 2012, 18, 3293-3304.	3.2	40
36	Adhesion molecules and differentiation syndrome: phenotypic and functional analysis of the effect of ATRA, As ₂ O ₃ , phenylbutyrate, and G-CSF in acute promyelocytic leukemia. <i>Haematologica</i> , 2007, 92, 1615-1622.	1.7	39

#	ARTICLE	IF	CITATIONS
37	Myeloid leukemia with promyelocytic features in transgenic mice expressing hCG-NuMA-RAR α . <i>Oncogene</i> , 2004, 23, 665-678.	2.6	38
38	The emerging story of acute lymphoblastic leukemia among the Latin American population – biological and clinical implications. <i>Blood Reviews</i> , 2019, 33, 98-105.	2.8	38
39	Halofuginone Has Anti-Proliferative Effects in Acute Promyelocytic Leukemia by Modulating the Transforming Growth Factor Beta Signaling Pathway. <i>PLoS ONE</i> , 2011, 6, e26713.	1.1	34
40	PRAME is a membrane and cytoplasmic protein aberrantly expressed in chronic lymphocytic leukemia and mantle cell lymphoma. <i>Leukemia Research</i> , 2006, 30, 1333-1339.	0.4	31
41	Monoclonal B-cell lymphocytosis in first-degree relatives of patients with sporadic (non-familial) chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2009, 147, 339-346.	1.2	31
42	All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies. <i>Annals of Hematology</i> , 2015, 94, 1347-1356.	0.8	31
43	IGF1R/IRS1 targeting has cytotoxic activity and inhibits PI3K/AKT/mTOR and MAPK signaling in acute lymphoblastic leukemia cells. <i>Cancer Letters</i> , 2019, 456, 59-68.	3.2	31
44	Systematic Review of Available CAR-T Cell Trials around the World. <i>Cancers</i> , 2022, 14, 2667.	1.7	31
45	Antinociception induced by intraperitoneal injection of gentamicin in rats and mice. <i>Pain</i> , 1990, 41, 365-371.	2.0	30
46	DIFFERENTIATION SYNDROME IN PROMYELOCYTIC LEUKEMIA : CLINICAL PRESENTATION, PATHOGENESIS AND TREATMENT. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2011, 3, e2011048.	0.5	30
47	Overexpression of EZH2 associates with a poor prognosis in chronic lymphocytic leukemia. <i>Blood Cells, Molecules, and Diseases</i> , 2015, 54, 97-102.	0.6	29
48	Analysis of the molecular genetics of acute promyelocytic leukemia in mouse models. <i>Seminars in Hematology</i> , 2001, 38, 54-70.	1.8	28
49	High β -Np73/TAp73 ratio is associated with poor prognosis in acute promyelocytic leukemia. <i>Blood</i> , 2015, 126, 2302-2306.	0.6	28
50	The Recognition of N-Glycans by the Lectin ArtinM Mediates Cell Death of a Human Myeloid Leukemia Cell Line. <i>PLoS ONE</i> , 2011, 6, e27892.	1.1	27
51	The presence of CD56/CD16 in T-cell acute lymphoblastic leukaemia correlates with the expression of cytotoxic molecules and is associated with worse response to treatment. <i>British Journal of Haematology</i> , 2009, 144, 223-229.	1.2	26
52	Disrupting membrane raft domains by alkylphospholipids. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2013, 1828, 1384-1389.	1.4	26
53	NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2V617F-positive myeloproliferative neoplasm cells. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 5.	7.1	26
54	EPIDEMIOLOGY AND TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA IN LATIN AMERICA. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2011, 3, e2011049.	0.5	25

#	ARTICLE	IF	CITATIONS
55	Outcome of acute myeloid leukemia patients with hyperleukocytosis in Brazil. <i>Medical Oncology</i> , 2010, 27, 1254-1259.	1.2	24
56	Linker for Activation of T-cell Family Member2 (LAT2) a Lipid Raft Adaptor Protein for AKT Signaling, Is an Early Mediator of Alkylphospholipid Anti-leukemic Activity. <i>Molecular and Cellular Proteomics</i> , 2012, 11, 1898-1912.	2.5	24
57	Inhibition of NF- κ B by Dehydroxymethylepoxyquinomicin Suppresses Invasion and Synergistically Potentiates Temozolomide and 13 C-Radiation Cytotoxicity in Glioblastoma Cells. <i>Chemotherapy Research and Practice</i> , 2013, 2013, 1-16.	1.6	24
58	Residual expression of SMYD2 and SMYD3 is associated with the acquisition of complex karyotype in chronic lymphocytic leukemia. <i>Tumor Biology</i> , 2016, 37, 9473-9481.	0.8	24
59	Characterization of acute lymphoblastic leukemia subtypes in Brazilian patients. <i>Leukemia Research</i> , 1996, 20, 349-355.	0.4	23
60	Flow cytometry characterization of leukemic phase of nasal NK/T-cell lymphoma in tumor biopsies and peripheral blood. <i>Haematologica</i> , 2007, 92, e24-e25.	1.7	23
61	Synthetic phosphoethanolamine has in vitro and in vivo anti-leukemia effects. <i>British Journal of Cancer</i> , 2013, 109, 2819-2828.	2.9	23
62	Differential expression of AURKA and AURKB genes in bone marrow stromal mesenchymal cells of myelodysplastic syndrome: correlation with G-banding analysis and FISH. <i>Experimental Hematology</i> , 2013, 41, 198-208.	0.2	22
63	(α)-Epigallocatechin-3-gallate induces apoptosis and differentiation in leukaemia by targeting reactive oxygen species and PIN1. <i>Scientific Reports</i> , 2021, 11, 9103.	1.6	22
64	Analysis of the molecular genetics of acute promyelocytic leukemia in mouse models. <i>Seminars in Hematology</i> , 2001, 38, 54-70.	1.8	22
65	Inhibition of the succinyl dehydrogenase complex in acute myeloid leukemia leads to a lactate-fuelled respiratory metabolic vulnerability. <i>Nature Communications</i> , 2022, 13, 2013.	5.8	22
66	Combining gene mutation with gene expression analysis improves outcome prediction in acute promyelocytic leukemia. <i>Blood</i> , 2019, 134, 951-959.	0.6	21
67	Methionine-induced hyperhomocysteinemia reverts fibrinolytic pathway activation in a murine model of acute promyelocytic leukemia. <i>Blood</i> , 2012, 120, 207-213.	0.6	20
68	Cardiac stunning as a manifestation of ATRA differentiation syndrome in acute promyelocytic leukemia. <i>Medical Oncology</i> , 2012, 29, 248-250.	1.2	20
69	Real-life Outcomes on Acute Promyelocytic Leukemia in Brazil – Early Deaths Are Still a Problem. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e116-e122.	0.2	20
70	Microgranular and t(11;17)/PLZF-RAR \pm variants of acute promyelocytic leukemia also present the flow cytometric pattern of CD13, CD34, and CD15 expression characteristic of PML-RAR \pm gene rearrangement. <i>American Journal of Hematology</i> , 2004, 76, 44-51.	2.0	19
71	The association of ICAM-1 Exon 6 (E469K) but not of ICAM-1 Exon 4 (G241R) and PECAM-1 Exon 3 (L125V) polymorphisms with the development of differentiation syndrome in acute promyelocytic leukemia. <i>Journal of Leukocyte Biology</i> , 2007, 82, 1340-1343.	1.5	19
72	Single-nucleotide polymorphism array (SNP-A) improves the identification of chromosomal abnormalities by metaphase cytogenetics in myelodysplastic syndrome. <i>Journal of Clinical Pathology</i> , 2017, 70, 435-442.	1.0	19

#	ARTICLE	IF	CITATIONS
73	Reactive oxygen species production triggers green tea-induced anti-leukaemic effects on acute promyelocytic leukaemia model. <i>Cancer Letters</i> , 2018, 414, 116-126.	3.2	19
74	Guidelines on the diagnosis and treatment for acute promyelocytic leukemia: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Guidelines Project: Associação Médica Brasileira - 2013. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2014, 36, 71-89.	0.7	18
75	Acute promyelocytic leukemia associated with the PLZF-RARA fusion gene: two additional cases with clinical and laboratorial peculiar presentations. <i>Medical Oncology</i> , 2012, 29, 2345-2347.	1.2	17
76	IRS1/Î²â€Catenin Axis Is Activated and Induces MYC Expression in Acute Lymphoblastic Leukemia Cells. <i>Journal of Cellular Biochemistry</i> , 2017, 118, 1774-1781.	1.2	17
77	Evaluation of the European LeukemiaNet recommendations for predicting outcomes of patients with acute myeloid leukemia treated in low- and middle-income countries (LMIC): A Brazilian experience. <i>Leukemia Research</i> , 2017, 60, 109-114.	0.4	17
78	The expression of Î³NTP73, TATP73 and TP53 genes in acute myeloid leukaemia is associated with recurrent cytogenetic abnormalities and in vitro susceptibility to cytarabine cytotoxicity. <i>British Journal of Haematology</i> , 2008, 142, 74-78.	1.2	16
79	Antibody-targeted horseradish peroxidase associated with indole-3-acetic acid induces apoptosis in vitro in hematological malignancies. <i>Leukemia Research</i> , 2011, 35, 657-662.	0.4	16
80	Halofuginone inhibits phosphorylation of SMAD-2 reducing angiogenesis and leukemia burden in an acute promyelocytic leukemia mouse model. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 65.	3.5	15
81	Targeting the Acute Myeloid Leukemia Stem Cells. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2010, 10, 104-110.	0.9	14
82	Reversine triggers mitotic catastrophe and apoptosis in K562 cells. <i>Leukemia Research</i> , 2016, 48, 26-31.	0.4	14
83	Metformin exerts multitarget antileukemia activity in JAK2V617F-positive myeloproliferative neoplasms. <i>Cell Death and Disease</i> , 2018, 9, 311.	2.7	14
84	The Glycolytic Gatekeeper PDK1 defines different metabolic states between genetically distinct subtypes of human acute myeloid leukemia. <i>Nature Communications</i> , 2022, 13, 1105.	5.8	14
85	The CEBPA gene is down-regulated in acute promyelocytic leukemia and its upstream promoter, but not the core promoter, is highly methylated. <i>Haematologica</i> , 2011, 96, 617-620.	1.7	13
86	Prognostic impact of KMT2E transcript levels on outcome of patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukaemia study. <i>British Journal of Haematology</i> , 2014, 166, 540-549.	1.2	13
87	Autophagy inhibition potentiates ruxolitinib-induced apoptosis in JAK2V617F cells. <i>Investigational New Drugs</i> , 2020, 38, 733-745.	1.2	13
88	Translocations t(X;14)(q28;q11) and t(Y;14)(q12;q11) in T-cell prolymphocytic leukemia. <i>International Journal of Laboratory Hematology</i> , 2009, 31, 453-456.	0.7	12
89	Interaction of 10-(octyloxy) decyl-2-(trimethylammonium) ethyl phosphate with mimetic membranes and cytotoxic effect on leukemic cells. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2010, 1798, 1714-1723.	1.4	12
90	Targeting the mitochondria in acute myeloid leukemia. <i>Applied Cancer Research</i> , 2017, 37, .	1.0	12

#	ARTICLE	IF	CITATIONS
91	Outcomes of HIV-associated Burkitt Lymphoma in Brazil: High treatment toxicity and refractoriness rates – A multicenter cohort study. <i>Leukemia Research</i> , 2020, 89, 106287.	0.4	12
92	CD10 and CD19 fluorescence intensity of B-cell precursors in normal and leukemic bone marrow. Clinical characterization of CD10+strong and CD10+weak common acute lymphoblastic leukemia. <i>Leukemia Research</i> , 1999, 23, 441-450.	0.4	11
93	The co-expression of PML/RAR alpha and AML1/ETO fusion genes is associated with ATRA resistance. <i>British Journal of Haematology</i> , 2005, 128, 407-409.	1.2	11
94	Apoptosis induction by (+)- α -tocopheryl succinate in the absence or presence of all-trans retinoic acid and arsenic trioxide in NB4, NB4-R2 and primary APL cells. <i>Leukemia Research</i> , 2009, 33, 958-963.	0.4	11
95	Results of FLT3 mutation screening and correlations with immunophenotyping in 169 Brazilian patients with acute myeloid leukemia. <i>Annals of Hematology</i> , 2010, 89, 225-228.	0.8	11
96	Aberrant levels of <i>SUV39H1</i> and <i>SUV39H2</i> methyltransferase are associated with genomic instability in chronic lymphocytic leukemia. <i>Environmental and Molecular Mutagenesis</i> , 2017, 58, 654-661.	0.9	11
97	Integrating clinical features with genetic factors enhances survival prediction for adults with acute myeloid leukemia. <i>Blood Advances</i> , 2020, 4, 2339-2350.	2.5	11
98	Improving the Treatment Outcome of Acute Promyelocytic Leukemia in Developing Countries through International Cooperative Network. Report On the International Consortium On Acute Promyelocytic Leukemia Study Group. <i>Blood</i> , 2009, 114, 6-6.	0.6	11
99	Characteristics and outcome of acute myeloid leukemia with uncommon retinoic acid receptor-alpha (RARA) fusion variants. <i>Blood Cancer Journal</i> , 2021, 11, 167.	2.8	11
100	Immunophenotype of normal and leukemic bone marrow B-precursors in a Brazilian population. A comparative analysis by quantitative fluorescence cytometry. <i>Brazilian Journal of Medical and Biological Research</i> , 2001, 34, 183-194.	0.7	10
101	Biological X-ray irradiator characterization for use with small animals and cells. <i>Brazilian Journal of Medical and Biological Research</i> , 2017, 50, e5848.	0.7	10
102	Granulocyte colony-stimulating factor and leukemogenesis. <i>Mediators of Inflammation</i> , 2004, 13, 145-150.	1.4	9
103	Treating acute promyelocytic leukaemia in Latin America: lessons from the International Consortium on Acute Leukaemia experience. <i>British Journal of Haematology</i> , 2017, 177, 979-983.	1.2	9
104	Paclitaxel induces Stathmin 1 phosphorylation, microtubule stability and apoptosis in acute lymphoblastic leukemia cells. <i>Heliyon</i> , 2017, 3, e00405.	1.4	9
105	GLP overexpression is associated with poor prognosis in Chronic Lymphocytic Leukemia and its inhibition induces leukemic cell death. <i>Investigational New Drugs</i> , 2018, 36, 955-960.	1.2	9
106	Mutational profile of ZBTB16/RARA-positive acute myeloid leukemia. <i>Cancer Medicine</i> , 2021, 10, 3839-3847.	1.3	9
107	Predictive factors associated with induction-related death in acute myeloid leukemia in a resource-constrained setting. <i>Annals of Hematology</i> , 2021, , 1.	0.8	9
108	Dose-dependent pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine. , 1998, 58, 340-341.		8

#	ARTICLE	IF	CITATIONS
109	Analysis of five polymorphic DNA markers for indirect genetic diagnosis of haemophilia A in the Brazilian population. <i>Haemophilia</i> , 2011, 17, e936-43.	1.0	8
110	Clinical impact of BAALC expression in high-risk acute promyelocytic leukemia. <i>Blood Advances</i> , 2017, 1, 1807-1814.	2.5	8
111	Unraveling KDM4 histone demethylase expression and its association with adverse cytogenetic findings in chronic lymphocytic leukemia. <i>Medical Oncology</i> , 2019, 36, 3.	1.2	8
112	The Combination of Gefitinib With ATRA and ATO Induces Myeloid Differentiation in Acute Promyelocytic Leukemia Resistant Cells. <i>Frontiers in Oncology</i> , 2021, 11, 686445.	1.3	8
113	CCR2 Plays a Protective Role in Rocio Virus-Induced Encephalitis by Promoting Macrophage Infiltration Into the Brain. <i>Journal of Infectious Diseases</i> , 2019, 219, 2015-2025.	1.9	8
114	Characterization of Myeloid or Lymphoid Acute Leukemia by a Chemiluminescence Assay. Comparison with Immunocytochemistry Using an Antimyeloperoxidase Antibody. <i>Acta Haematologica</i> , 1993, 90, 19-24.	0.7	7
115	Blastoid mantle cell lymphoma with t(2;8) (p12;q24). <i>Leukemia and Lymphoma</i> , 2007, 48, 2079-2082.	0.6	7
116	Acute myeloid leukemia (AML-M2) with t(5;11)(q35;q13) and normal expression of cyclin D1. <i>Cancer Genetics and Cytogenetics</i> , 2007, 172, 154-157.	1.0	7
117	The role of micro-ribonucleic acids in normal hematopoiesis and leukemic T-lymphogenesis. <i>Brazilian Journal of Medical and Biological Research</i> , 2010, 43, 619-626.	0.7	7
118	Molecular basis for the diagnosis and treatment of acute promyelocytic leukemia. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2012, 34, 134-139.	0.7	7
119	Reduced SLIT2 is Associated with Increased Cell Proliferation and Arsenic Trioxide Resistance in Acute Promyelocytic Leukemia. <i>Cancers</i> , 2020, 12, 3134.	1.7	7
120	NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia. <i>Investigational New Drugs</i> , 2021, 39, 736-746.	1.2	7
121	Asynchronous expression of myeloid antigens in leukemic cells in a PML/RARalpha transgenic mouse model. <i>Brazilian Journal of Medical and Biological Research</i> , 2006, 39, 615-620.	0.7	7
122	Intracranial Castleman's disease presenting as hypopituitarism. <i>Neuroradiology</i> , 2004, 46, 830-833.	1.1	6
123	Smudge cells in peripheral blood smears did not differentiate chronic lymphocytic leukemia from other B-cell chronic lymphoproliferative diseases. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2009, 31, 333-336.	0.7	6
124	Comparative analysis of the pathological events involved in immune and non-immune TRALI models. <i>Vox Sanguinis</i> , 2012, 103, 309-321.	0.7	6
125	Philadelphia-positive B-lymphoblastic leukemia in a middle-income country - A real-world multicenter cohort. <i>Leukemia Research</i> , 2021, 110, 106666.	0.4	6
126	A multicenter comparative acute myeloid leukemia study: can we explain the differences in the outcomes in resource-constrained settings?. <i>Leukemia and Lymphoma</i> , 2021, 62, 147-157.	0.6	6

#	ARTICLE	IF	CITATIONS
127	Thrombin Generation and Fibrinolytic Activity in Microparticles In Acute Promyelocytic Leukemia. <i>Blood</i> , 2013, 122, 3620-3620.	0.6	6
128	Early Hematopoietic Progenitors of Dkc1 Hypomorphic Mutant Mice Display Decreased Proliferation Rate and an Impaired Control of Serine/Arginine-Rich Splicing Factor 4 (Srsf4) Translation. <i>Blood</i> , 2014, 124, 2937-2937.	0.6	6
129	STMN1 is highly expressed and contributes to clonogenicity in acute promyelocytic leukemia cells. <i>Investigational New Drugs</i> , 2022, 40, 438-452.	1.2	6
130	Antinociception induced by intracerebroventricular or intrathecal administration of gentamicin in rats. <i>General Pharmacology</i> , 1992, 23, 481-485.	0.7	5
131	Segmental amplification of MLL gene associated with high expression of AURKA and AURKB genes in a case of acute monoblastic leukemia with complex karyotype. <i>Cancer Genetics and Cytogenetics</i> , 2010, 198, 62-65.	1.0	5
132	Granulocytic sarcoma of the stomach: Relapse after hematopoietic stem-cell transplantation for chronic myeloid leukemia. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2010, 3, 94-98.	0.6	5
133	The impact of medical education and networking on the outcome of leukemia treatment in developing countries. The experience of International Consortium on Acute Promyelocytic Leukemia (IC-APL). <i>Hematology</i> , 2012, 17, s36-s38.	0.7	5
134	Genetic Mutations in Patients with Acute Myeloid Leukemia and Leukostasis. <i>Acta Haematologica</i> , 2013, 130, 95-97.	0.7	5
135	Association between the TP53 Arg72Pro polymorphism and clinical outcomes in acute myeloid leukemia. <i>Haematologica</i> , 2017, 102, e43-e46.	1.7	5
136	Telomere length analysis in monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia Binet A. <i>Brazilian Journal of Medical and Biological Research</i> , 2017, 50, e6019.	0.7	5
137	Outcomes and second neoplasms in hairy cell leukemia: A retrospective cohort. <i>Leukemia Research</i> , 2019, 83, 106165.	0.4	5
138	NTAL is associated with treatment outcome, cell proliferation and differentiation in acute promyelocytic leukemia. <i>Scientific Reports</i> , 2020, 10, 10315.	1.6	5
139	Low expression of ZHX1 and ZHX2 impacts on the prognosis of chronic lymphocytic leukemia. <i>Biomarker Research</i> , 2021, 9, 10.	2.8	5
140	MLL5 improves ATRA driven differentiation and promotes xenotransplant engraftment in acute promyelocytic leukemia model. <i>Cell Death and Disease</i> , 2021, 12, 371.	2.7	5
141	Thalidomide + Dexamethasone as Maintenance after Single Autologous Stem Cell Transplantation Improves Progression-Free Survival (PFS) in Advanced Multiple Myeloma. A Prospective Brazilian Randomized Trial. <i>Blood</i> , 2008, 112, 3703-3703.	0.6	5
142	Characterization Of Leukemic Stem Cells In AML Cell Lines Using ALDH Staining. <i>Blood</i> , 2013, 122, 5409-5409.	0.6	5
143	Novel inhibitor of hematopoietic cell kinase as a potential therapeutic agent for acute myeloid leukemia. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1909-1921.	2.0	5
144	Adult acute lymphoblastic leukemia in a resource-constrained setting: outcomes after expansion of genetic evaluation. <i>Hematology</i> , 2022, 27, 396-403.	0.7	5

#	ARTICLE	IF	CITATIONS
145	Guidelines on the treatment of acute myeloid leukemia: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Revista Brasileira De Hematologia E Hemoterapia, 2016, 38, 58-74.	0.7	4
146	The lipid raft protein NTAL participates in AKT signaling in mantle cell lymphoma. Leukemia and Lymphoma, 2019, 60, 2658-2668.	0.6	4
147	Toxicity Profile of PEG-Asparaginase in Adult Patients With Acute Lymphoblastic Leukemia in Brazil: A Multicenter Cross-Sectional Study. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e523-e528.	0.2	4
148	Tissue Factor Pathway Inhibitor (TFPI) May be Another Important Factor in the Coagulopathy in Acute Promyelocytic Leukemia (APL). Blood, 2015, 126, 2278-2278.	0.6	4
149	Acute Promyelocytic Leukemia. , 2015, , 1-4.		4
150	Salvage treatment for refractory or relapsed acute myeloid leukemia: a 10-year single-center experience. Clinics, 2020, 75, e1566.	0.6	4
151	Activity of Free and Liposomal Antimony Trioxide in the Acute Promyelocytic Leukemia Cell Line NB4. Anticancer Research, 2021, 41, 6061-6065.	0.5	4
152	Myeloid Immune Cells CARrying a New Weapon Against Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 784421.	1.8	4
153	Coagulation abnormalities in acute promyelocytic leukemia. Revista Brasileira De Hematologia E Hemoterapia, 2009, 31, .	0.7	3
154	FISH analysis for TET2 deletion in a cohort of 362 Brazilian myeloid malignancies: correlation with karyotype abnormalities. Medical Oncology, 2013, 30, 483.	1.2	3
155	Development and Evaluation of a Hematology-Oriented Clinical Research Training Program in Latin America. Journal of Cancer Education, 2017, 32, 845-849.	0.6	3
156	Comparison of microRNA expression in high-count monoclonal B-cell lymphocytosis and Binet A chronic lymphocytic leukemia. Revista Brasileira De Hematologia E Hemoterapia, 2017, 39, 237-243.	0.7	3
157	Impact of the ICAL on the treatment of acute leukemia. Blood Advances, 2017, 1, 516-516.	2.5	3
158	Modeling dynamics and alternative treatment strategies in acute promyelocytic leukemia. PLoS ONE, 2019, 14, e0221011.	1.1	3
159	Decreased Activity of NK Cells in Myeloproliferative Neoplasms. Blood, 2015, 126, 1637-1637.	0.6	3
160	Î²Np73 overexpression promotes resistance to apoptosis but does not cooperate with PML/RARA in the induction of an APL-leukemic phenotype. Oncotarget, 2017, 8, 8475-8483.	0.8	3
161	The expression of the CD56 antigen is associated with poor prognosis in patients with acute myeloid leukemia. Revista Brasileira De Hematologia E Hemoterapia, 2011, 33, 176-177.	0.7	3
162	Immunophenotype of acute lymphoblastic leukemia in minorities – analysis from the SEER database. Hematological Oncology, 2022, 40, 106-111.	0.8	3

#	ARTICLE	IF	CITATIONS
163	COVID-19 induced follicular lymphoma remission. <i>Hematology, Transfusion and Cell Therapy</i> , 2022, 44, 291-292.	0.1	3
164	Tetrasomy 8 in a patient with chronic lymphocytic leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2010, 198, 166-169.	1.0	2
165	The results of the International Consortium on Acute Promyelocytic Leukemia: a 'proof of concept' of networking as a strategy to improve the outcome of treatment of hematological malignancies in developing countries. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2013, 35, 1-2.	0.7	2
166	The experience of the International Consortium on Acute Promyelocytic Leukemia in monitoring minimal residual disease in acute promyelocytic leukaemia. <i>British Journal of Haematology</i> , 2018, 180, 915-918.	1.2	2
167	CCAAT/enhancer-binding protein alpha (CEBPA) gene haploinsufficiency does not alter hematopoiesis or induce leukemia in Lck-CALM/AF10 transgenic mice. <i>Brazilian Journal of Medical and Biological Research</i> , 2019, 52, e8424.	0.7	2
168	Interleukin-8 is not a predictive biomarker for the development of the acute promyelocytic leukemia differentiation syndrome. <i>BMC Cancer</i> , 2020, 20, 821.	1.1	2
169	Molecular-Based Score inspired on metabolic signature improves prognostic stratification for myelodysplastic syndrome. <i>Scientific Reports</i> , 2021, 11, 1675.	1.6	2
170	Obatoclox reduces cell viability of acute myeloid leukemia cell lines independently of their sensitivity to venetoclax. <i>Hematology, Transfusion and Cell Therapy</i> , 2021, 44, 124-124.	0.1	2
171	Crosstalk between hnRNP K and SET in ATRA-induced differentiation in acute promyelocytic leukemia. <i>FEBS Open Bio</i> , 2021, 11, 2019-2032.	1.0	2
172	Microparticles in Acute Promyelocytic Leukemia,. <i>Blood</i> , 2011, 118, 3346-3346.	0.6	2
173	TLR9 Priming Promotes Proliferation Of Mesenchymal Stem Cells and Restores The Immunosuppressive Activity Impaired By TLR4 Priming: Potential Involvement Of Non-Canonical NF-Kb Signaling. <i>Blood</i> , 2013, 122, 2458-2458.	0.6	2
174	Treatment Outcome of Brazilian Patients with Acute Myeloid Leukemia According to the New European LeukemiaNet Recommendations. <i>Blood</i> , 2011, 118, 3146-3146.	0.6	2
175	Acute Lymphocytic Leukemia in the Latin American Population. <i>Blood</i> , 2018, 132, 5282-5282.	0.6	2
176	NSD1 and NSD2 Transcriptional Levels Might Predict Clinical Outcome in AML Patients. <i>Blood</i> , 2018, 132, 5257-5257.	0.6	2
177	Viability of Chimeric Antigen Receptor T Cell Therapy in Latin America. <i>Blood</i> , 2021, 138, 4843-4843.	0.6	2
178	The higher expression of β 1 and β 2 isoforms of the human glucocorticoid receptor in leukemic B-progenitors compared to normal CD10+ BM cells does not correlate with methylprednisolone-induced apoptosis. <i>Leukemia</i> , 2004, 18, 890-892.	3.3	1
179	Differentiation syndrome in acute promyelocytic leukemia: pathogenesis and risk factors. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 0, 30, .	0.7	1
180	A 23-year-old woman with 11q-chronic lymphocytic leukemia. <i>Medical Oncology</i> , 2011, 28, 1534-1536.	1.2	1

#	ARTICLE	IF	CITATIONS
181	Identification of a new translocation that disrupts the RUNX1 gene in a patient with de novo acute myeloid leukemia. <i>Medical Oncology</i> , 2012, 29, 1114-1118.	1.2	1
182	Importance of attaining good acute promyelocytic leukemia outcome in developing countries: the IC-APL experience. <i>International Journal of Hematologic Oncology</i> , 2013, 2, 269-271.	0.7	1
183	HIGH GRADE GLIOMAS AND DIPG. <i>Neuro-Oncology</i> , 2014, 16, i40-i59.	0.6	1
184	Acute myeloid leukemia with e1a2 BCR-ABL1 fusion gene: two cases with peculiar molecular and clinical presentations. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2017, 39, 379-384.	0.7	1
185	Comparative genomic analysis of PML and RARA breakpoints in paired diagnosis/relapse samples of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. <i>Leukemia and Lymphoma</i> , 2018, 59, 1268-1270.	0.6	1
186	The Expression of NTAL and Its Protein Interactors Is Associated With Clinical Outcomes in Acute Myeloid Leukemia. <i>Molecular and Cellular Proteomics</i> , 2021, 20, 100091.	2.5	1
187	Clinical Features and Outcome of 148 Patients with Acute Promyelocytic Leukemia in Brazil. <i>Blood</i> , 2006, 108, 3326-3326.	0.6	1
188	Halofuginone Exerts Antiproliferative and Antiangiogenic Actions on Acute Promyelocytic Leukemia Cells through Modulation of the TGF β Pathway. <i>Blood</i> , 2007, 110, 2850-2850.	0.6	1
189	High Mir-221 Expression Is Associated with Poorer Treatment Outcome of Patients with T-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2011, 118, 1439-1439.	0.6	1
190	The Use of Cyclosporine in Association with Chemotherapy As Induction Treatment in Patients with Acute Myeloid Leukemia (AML) and High Rhodamine Efflux at Diagnosis Results in Higher Complete Hematological Remission Rates, but Does Not Prolong Overall Survival. <i>Blood</i> , 2015, 126, 4896-4896.	0.6	1
191	Association of Setmar Expression with Clinical Characteristics in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 4815-4815.	0.6	1
192	Impact of Treatment Free Remission (TFR) with Nilotinib in 2nd Line for Chronic Myeloid Leukemia on Savings That May Fund All BCR-ABL Tests in the Brazilian Public Healthcare System during and after Nilotinib Treatment. <i>Blood</i> , 2018, 132, 4760-4760.	0.6	1
193	C/Ebpg (CCAAT/Enhancer Binding Protein Gamma) Balances Cytotoxic and Secretory Potential of Natural Killer Cells. <i>Blood</i> , 2018, 132, 3721-3721.	0.6	1
194	Improving the Outcomes of Acute Promyelocytic Leukemia in a Limited Resources Setting: The Benefit of Early ATRA Administration in 30-Day Survival. <i>Blood</i> , 2018, 132, 5874-5874.	0.6	1
195	Metformin Suppress Cellular and Molecular Processes Related to Maintenance and Proliferation of Myeloproliferative Neoplasm Stem Cell. <i>Blood</i> , 2019, 134, 1682-1682.	0.6	1
196	Challenges in Diagnosis and Treatment of Systemic Amyloidosis: 10 Years of Experience in a Public Brazilian University Center. <i>Blood</i> , 2020, 136, 6-8.	0.6	1
197	Telehealth in Hematopoietic Cell Transplantation: Perspective from Patients at a Public Hospital in Brazil. <i>Blood</i> , 2020, 136, 26-26.	0.6	1
198	Differential cytotoxic activity of pharmacological inhibitors of IGF1R-related pathways in JAK2V617F driven cells. <i>Toxicology in Vitro</i> , 2022, 83, 105384.	1.1	1

#	ARTICLE	IF	CITATIONS
199	977 Dehydroxymethylepoxyquinomicin, a Novel Inhibitor of NF- κ B Efficiently Suppresses Invasion and Radiosensitizes Glioblastoma Cells. <i>European Journal of Cancer</i> , 2012, 48, S235.	1.3	0
200	Phosphatidylinositol-4, 5-biphosphate 3-kinase, catalytic subunit alpha (PI3KCA) and microsatellite instability in ovarian clear cell carcinoma, clinical correlation. <i>Annals of Oncology</i> , 2016, 27, vi304.	0.6	0
201	Molecular and hematologic relapses in adult patients with acute promyelocytic leukemia: a cohort study. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2017, 39, 46-51.	0.7	0
202	The application of an integrated clinical, cytogenetic, and molecular risk stratification for acute myeloid leukemia patients using a central laboratory in a Brazilian multicentric study. <i>Blood Advances</i> , 2017, 1, 86-89.	2.5	0
203	Feasibility of minimal residual disease studies by multiparametric flow cytometry for acute myeloid leukemia in a developing country. <i>Blood Advances</i> , 2017, 1, 80-83.	2.5	0
204	35 years of the Brazilian Journal of Medical and Biological Research. <i>Brazilian Journal of Medical and Biological Research</i> , 2017, 50, e6153.	0.7	0
205	APL in Developing Countries: A Chemotherapy-Based Approach. , 2018, , 211-216.		0
206	Artemisinins induce endoplasmic reticulum stress in acute leukaemia cells in vitro and in vivo. <i>EJHaem</i> , 2021, 2, 818.	0.4	0
207	Molecular basis of Acute Myelogenous Leukemia. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2002, 24, .	0.7	0
208	TRATAMENTO DAS INFECÇÕES EM PACIENTES COM PANCITOPENIA SECUNDÁRIA A TRATAMENTO CITORREDUTOR. <i>Medicina</i> , 2003, 36, 446.	0.0	0
209	Histone Deacetylase Inhibitors and Filgrastim Do Not Synergize with ATRA in the Induction of Changes of Acute Promyelocytic Leukemia Cells Adhesive Properties.. <i>Blood</i> , 2004, 104, 2548-2548.	0.6	0
210	The Structure of the Gene for miR-223 in Humans, a MicroRNA Highly Expressed in Hematopoietic Tissues.. <i>Blood</i> , 2005, 106, 4243-4243.	0.6	0
211	Acute Myeloid Leukemia (AML-M2) with a Novel Translocation t(5;11)(q35;q13) and Normal Expression of Cyclin D1.. <i>Blood</i> , 2005, 106, 4538-4538.	0.6	0
212	In Vivo Analysis of the Anti-Leukemic Activity of Alpha-Tocopherol in Acute Promyelocytic Leukemia.. <i>Blood</i> , 2006, 108, 2011-2011.	0.6	0
213	Adhesion Molecules in Normal Hematopoiesis and Leukemia. , 2010, , 359-373.		0
214	Acute Promyelocytic Leukemia. , 2011, , 32-35.		0
215	Comparison Between RT-PCR and RQ-PCR for Minimal Residual Disease Detection in Acute Promyelocytic Leukemia: The International Consortium on Acute Promyelocytic Leukemia (IC-APL) Experience.. <i>Blood</i> , 2011, 118, 3552-3552.	0.6	0
216	^{73}Np / ^{73}TAp Expression Ratio Is Associated with Poor Outcome in Acute Promyelocytic Leukemia.. <i>Blood</i> , 2011, 118, 3536-3536.	0.6	0

#	ARTICLE	IF	CITATIONS
217	Flow Cytometry Quantification of Leukemic Stem Cells Is Associated with Risk Stratification and May Be Useful for Minimal Residual Disease in Acute Myeloid Leukemia. <i>Blood</i> , 2011, 118, 1470-1470.	0.6	0
218	Aberrant Expression of the MLL5, BAALC, ID1, and WT1 Genes Is Associated with Higher Induction Mortality and Poorer Overall Survival in Acute Promyelocytic Leukemia Patients Treated with ATRA and Anthracycline-Based Chemotherapy: An International Consortium On Acute Promyelocytic Leukemia Study. <i>Blood</i> , 2012, 120, 1407-1407.	0.6	0
219	Genome-Wide Methylation Analysis of Myeloid Progenitors in Normal Bone Marrow and in Acute Promyelocytic Leukemia At Diagnosis and in Hematological Remission. <i>Blood</i> , 2012, 120, 4611-4611.	0.6	0
220	Generation of Functional Regulatory T Cells From Umbilical Cord Blood Naïve T Cells: Potential Role of Hydroxymethylation in the Epigenetic Reprograming and Transcriptional Induction of FoxP3. <i>Blood</i> , 2012, 120, 4835-4835.	0.6	0
221	The Transcripts Of Platelet-Endothelial Adhesion Molecules and Inflammatory Chemokine Activation Pathway Molecules Are Hyperexpressed In The Bone Marrow Of Acute Promyelocytic Leukemia Patients Presenting Severe Coagulopathy. <i>Blood</i> , 2013, 122, 2574-2574.	0.6	0
222	Telomere Length In Acute Promyelocytic Leukemia. <i>Blood</i> , 2013, 122, 1348-1348.	0.6	0
223	Prognostic Impact Of MLL5 transcript Levels On Outcome Of Patients With Acute Promyelocytic Leukemia Treated With All-Trans Retinoic Acid and Anthracycline-Based Chemotherapy: An International Consortium On Acute Promyelocytic Leukemia Study. <i>Blood</i> , 2013, 122, 2586-2586.	0.6	0
224	A randomized double-blind phase III pivotal study of febuxostat (FEB) versus allopurinol (ALL) in the prevention of tumor lysis syndrome (TLS): Florence study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9641-9641.	0.8	0
225	Comparison of angiopoietin-1 and -2 and VEGF expression in bone marrow and peripheral blood leukemic cells of patients with acute promyelocytic leukemia.. <i>Journal of Clinical Oncology</i> , 2014, 32, 7079-7079.	0.8	0
226	Decision Driven Factors for Allopurinol Dosage in Tumor Lysis Syndrome Prophylaxis: The European Experience of the Florence Pivotal Study. <i>Blood</i> , 2014, 124, 5979-5979.	0.6	0
227	Feasibility of Implementing Minimal Residual Disease Monitoring in Acute Promyelocytic Leukemia Patients Treated in Developing Countries. <i>Blood</i> , 2014, 124, 5354-5354.	0.6	0
228	LAT2, a Lipid Raft Protein That Participates in AKT Phosphorylation in Mantle Cell Lymphoma, Is a Target for Perifosine Chemotherapy. <i>Blood</i> , 2014, 124, 923-923.	0.6	0
229	Effect of tumor-associated macrophages on neoplastic progression in sepsis-surviving mice through CXCL12/CXCR4.. <i>Journal of Clinical Oncology</i> , 2015, 33, e22107-e22107.	0.8	0
230	Pharmacological IRS1/2 Inhibition Reduces Cell Viability in BCR-ABL1 Positive Cells. <i>Blood</i> , 2015, 126, 2772-2772.	0.6	0
231	Telomere Dynamics in Monoclonal B-Cell Lymphocytosis and Binet a Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 5266-5266.	0.6	0
232	Phosphatidylinositol-4, 5-biphosphate 3-kinase, catalytic subunit alpha (<i>PI3KCA</i>) and microsatellite instability in ovarian clear cell carcinoma, clinical correlation.. <i>Journal of Clinical Oncology</i> , 2016, 34, e17061-e17061.	0.8	0
233	Pharmacological IRS1/2 Inhibition Induces Apoptosis in BCR-ABL1T315I mutant Cells. <i>Blood</i> , 2016, 128, 1886-1886.	0.6	0
234	ROS Production Triggers Anti-Leukemic Effects of Green Tea. <i>Blood</i> , 2016, 128, 5219-5219.	0.6	0

#	ARTICLE	IF	CITATIONS
235	Pharmacological IGF1R/IRS Inhibitor, NT157, Effectively Induces Apoptosis and CDKN1A Expression in Acute Lymphoblastic Leukemia Cells. <i>Blood</i> , 2016, 128, 3971-3971.	0.6	0
236	Multitarget Antileukemic Effects of Metformin in Myeloproliferative Neoplasm Cells: Inhibition of JAK2/STAT Signaling and Mitochondrial Activity. <i>Blood</i> , 2016, 128, 1960-1960.	0.6	0
237	Nuclear SET Domain (NSD) Protein Lysine Methyltransferases (KMT) Family Members Expression in Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 5097-5097.	0.6	0
238	WHO-2016 Classification in ALL By Cytogenetics, FISH and Molecular Biology - Experience of Two Reference Centers in Brazil. <i>Blood</i> , 2018, 132, 5288-5288.	0.6	0
239	Clinical, Cytogenetic and Immunophenotype Distribution of Adult Acute Lymphoblastic Leukemia Among Latinos â€” a Report from a Large Single Institution Cohort in Southern California. <i>Blood</i> , 2018, 132, 2816-2816.	0.6	0
240	Autophagy Inhibition Potentiates Ruxolitinib-Induced Apoptosis in JAK2V617F Cells. <i>Blood</i> , 2018, 132, 1788-1788.	0.6	0
241	Clinical Impact and Therapeutic Opportunity of Insulin Receptor Substrates 1/2 in Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 1512-1512.	0.6	0
242	Slit-Robo Pathway Is Clinically Relevant and May Represent a Potential Target in Acute Promyelocytic Leukemia. <i>Blood</i> , 2018, 132, 1533-1533.	0.6	0
243	KMT2E-Mediated Epigenetic Reprogramming Promotes the Sensitivity to All-Trans Retinoic Acid and Increases the Granulocytic Differentiation in AML Cells. <i>Blood</i> , 2018, 132, 3838-3838.	0.6	0
244	Metformin treatment Overcomes ATRA-Resistance in Acute Promyelocytic Leukemia and Increases FOXO3A Expression. <i>Blood</i> , 2018, 132, 1532-1532.	0.6	0
245	Abnormal Distribution and Function of NK Cells Subsets May Lead to Impaired Tumor Surveillance in a JAK2V617F Myeloproliferative Neoplasm Model. <i>Blood</i> , 2018, 132, 4335-4335.	0.6	0
246	Epigallocatechin-3-Gallate Induces Cellular Differentiation and Reduces Leukemia Burden in PML/Rar α Mice By Increasing Reactive Oxygen Species and Reducing PIN1 Expression. <i>Blood</i> , 2019, 134, 5765-5765.	0.6	0
247	Clinical and Functional Studies Reveal That TP73 Isoforms Levels Are Associated with Prognosis and RA-Resistance in Acute Promyelocytic Leukemia. <i>Blood</i> , 2019, 134, 2719-2719.	0.6	0
248	Reduced SLIT2 Are Associated with Increased Cell Proliferation and Arsenic Trioxide Resistance in APL Cells. <i>Blood</i> , 2019, 134, 5165-5165.	0.6	0
249	IGF1R-IRS1/2 Signaling Pathway Is a Potential Target for FLT3-Mutated Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 2689-2689.	0.6	0
250	MN1 Expression Is an Independent Prognostic Marker in FLT3-Mutated Acute Myeloid Leukemia and Is Involved in the Resistance to FLT3 Inhibitors. <i>Blood</i> , 2019, 134, 1403-1403.	0.6	0
251	Efficacy of the Pan-Bcl-2 Inhibitor (Obatoclax) As a Single Agent to Treat Myeloproliferative Neoplasm in JAK2V617F Murine Transplantation Model. <i>Blood</i> , 2019, 134, 2977-2977.	0.6	0
252	Combining Clinical Features with Genetic Factors Improves Survival Prediction for Adults with Acute Myeloid Leukemia: Validation of a New Score System in 3 Cohorts. <i>Blood</i> , 2019, 134, 2602-2602.	0.6	0

#	ARTICLE	IF	CITATIONS
253	Extranodal NK/T Cell Lymphoma Nasal Type: A Cohort Study from Latin America. <i>Blood</i> , 2019, 134, 5284-5284.	0.6	0
254	Retrospective Comparison between MEC and FLAG-Ida Regimens for Refractory or Relapsed Acute Myeloid Leukemia in Adults. <i>Blood</i> , 2019, 134, 1354-1354.	0.6	0
255	Molecular-Based Score Inspired on Metabolic Signature Improves Prognostic Stratification for Myelodysplastic Syndrome. <i>Blood</i> , 2019, 134, 4257-4257.	0.6	0
256	Outcomes of HIV-Associated Burkitt Lymphoma in Brazil: High Treatment Toxicity and Refractoriness Rates - a Multicenter Cohort Study. <i>Blood</i> , 2019, 134, 1616-1616.	0.6	0
257	Arsenic Trioxide Abrogate MN1 Mediated RA-Resistance in Acute Promyelocytic Leukemia. <i>Blood</i> , 2019, 134, 5166-5166.	0.6	0
258	A Novel Chemical Compound Inhibiting Hematopoietic Cell Kinase (iHCK) Has a Synergic Effect with Azacytidine (Aza) or Cytarabine (Ara-C) for Acute Myeloid Leukemia Treatment. <i>Blood</i> , 2019, 134, 4650-4650.	0.6	0
259	Associa�o Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. VIII: CAR-T cells: preclinical development - Safety and efficacy evaluation. <i>Hematology, Transfusion and Cell Therapy</i> , 2021, 43, S54-S63.	0.1	0
260	Treatment with the Recombinant SLIT2 Protein Delays AML Leukemogenesis In Vivo. <i>Blood</i> , 2021, 138, 2368-2368.	0.6	0
261	Phenformin increases early hematopoietic progenitors in the Jak2V617F murine model. <i>Investigational New Drugs</i> , 2022, , 1.	1.2	0
262	Clinical, Laboratory, and Genetic Features of Erdheim-Chester Disease Patients from Two Reference Centers in a Developing Country. <i>Blood</i> , 2020, 136, 22-23.	0.6	0
263	Assessing Early Mortality in Intensively-Treated Acute Myeloid Leukemia in a Developing Country: Genetic, Laboratory Findings, and Comorbidities Add Prognostic Information. <i>Blood</i> , 2020, 136, 5-6.	0.6	0
264	Chronic Myeloid Leukemia: Comparison of Survival between Pregnant and Non-Pregnant Women. <i>Blood</i> , 2020, 136, 37-38.	0.6	0